middle.news
How Paradigm’s New Oral Therapy Could Transform Early Osteoarthritis Treatment
8:41am on Thursday 26th of June, 2025 AEST
•
Healthcare
Read Story
How Paradigm’s New Oral Therapy Could Transform Early Osteoarthritis Treatment
8:41am on Thursday 26th of June, 2025 AEST
Key Points
Acquisition of Proteobioactives grants global patent rights for oral PPS and COX-2 inhibitor combo
Therapy targets early-stage osteoarthritis in human and veterinary markets
Preliminary pilot data show meaningful pain reduction in hand and knee OA
Milestone-based payments tied to clinical trial and regulatory successes
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PARADIGM BIOPHARMACEUTICALS LIMITED.. (ASX:PAR)
OPEN ARTICLE